Jefferies Financial Group Inc. Makes New Investment in Illumina, Inc. $ILMN

Jefferies Financial Group Inc. purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,522 shares of the life sciences company’s stock, valued at approximately $443,000.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Elyxium Wealth LLC acquired a new stake in Illumina in the 4th quarter valued at approximately $25,000. Fiduciary Financial Advisors acquired a new position in Illumina during the 2nd quarter worth approximately $26,000. Keating Financial Advisory Services Inc. acquired a new position in Illumina during the 2nd quarter worth approximately $32,000. Quarry LP bought a new position in shares of Illumina during the 3rd quarter worth approximately $32,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Illumina in the fourth quarter valued at approximately $33,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Down 0.9%

Shares of ILMN stock opened at $213.63 on Tuesday. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $231.81. The stock has a market cap of $32.26 billion, a price-to-earnings ratio of 39.86, a PEG ratio of 3.03 and a beta of 1.44. The firm’s 50-day moving average is $195.10 and its 200-day moving average is $156.54. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period last year, the firm posted $1.19 earnings per share. The business’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Insider Buying and Selling at Illumina

In other Illumina news, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the transaction, the insider directly owned 20,338 shares of the company’s stock, valued at $4,067,600. The trade was a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 138,379 shares of Illumina stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $228.89, for a total transaction of $31,673,569.31. Following the sale, the director directly owned 1,033,910 shares of the company’s stock, valued at $236,651,659.90. The trade was a 11.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,799,688 shares of company stock valued at $379,517,231 in the last quarter. 2.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages recently commented on ILMN. JPMorgan Chase & Co. increased their target price on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Guggenheim boosted their price target on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Citigroup increased their price objective on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Piper Sandler restated an “overweight” rating and issued a $225.00 price objective (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. Finally, Stifel Nicolaus lifted their target price on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.